Allstate Corporation’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.29M | Sell |
6,878
-4,075
| -37% | -$2.77M | 0.04% | 259 |
|
|
2026
Q1 | $8.46M | Buy |
10,953
+3,289
| +43% | +$2.52M | 0.09% | 137 |
|
|
2025
Q4 | $5.92M | Buy |
7,664
+3,889
| +103% | +$2.64M | 0.08% | 153 |
|
|
2025
Q3 | $2.12M | Buy |
+3,775
| New | +$2.13M | 0.05% | 213 |
|
|
2025
Q2 | – | Sell |
-3,525
| Closed | -$2.24M | – | 483 |
|
|
2025
Q1 | $2.24M | Buy |
3,525
+330
| +10% | +$227K | 0.07% | 187 |
|
|
2024
Q4 | $2.28M | Buy |
+3,195
| New | +$2.68M | 0.07% | 162 |
|
|
2024
Q3 | – | Sell |
-355
| Closed | -$373K | – | 202 |
|
|
2024
Q2 | $373K | Hold |
355
| – | – | 0.03% | 148 |
|
|
2024
Q1 | $342K | Sell |
355
-6
| -2% | -$5.71K | 0.02% | 156 |
|
|
2023
Q4 | $317K | Sell |
361
-10
| -3% | -$8.23K | 0.02% | 156 |
|
|
2023
Q3 | $305K | Hold |
371
| – | – | 0.02% | 151 |
|
|
2023
Q2 | $267K | Sell |
371
-2
| -0.5% | -$1.54K | 0.02% | 173 |
|
|
2023
Q1 | $306K | Sell |
373
-3,950
| -91% | -$2.98M | 0.02% | 150 |
|
|
2022
Q4 | $3.12M | Buy |
4,323
+76
| +2% | +$56.1K | 0.09% | 145 |
|
|
2022
Q3 | $2.93M | Buy |
4,247
+200
| +5% | +$126K | 0.08% | 138 |
|
|
2022
Q2 | $2.39M | Sell |
4,047
-132
| -3% | -$85.8K | 0.07% | 163 |
|
|
2022
Q1 | $2.92M | Sell |
4,179
-5,042
| -55% | -$3.19M | 0.08% | 185 |
|
|
2021
Q4 | $5.82M | Buy |
9,221
+8,478
| +1,141% | +$5.21M | 0.11% | 142 |
|
|
2021
Q3 | $450K | Sell |
743
-170
| -19% | -$106K | 0.02% | 533 |
|
|
2021
Q2 | $510K | Sell |
913
-369
| -29% | -$187K | 0.02% | 522 |
|
|
2021
Q1 | $607K | Buy |
1,282
+97
| +8% | +$47.2K | 0.02% | 481 |
|
|
2020
Q4 | $572K | Sell |
1,185
-762
| -39% | -$411K | 0.02% | 458 |
|
|
2020
Q3 | $1.09M | Sell |
1,947
-996
| -34% | -$604K | 0.04% | 212 |
|
|
2020
Q2 | $1.83M | Buy |
2,943
+852
| +41% | +$484K | 0.06% | 126 |
|
|
2020
Q1 | $1.02M | Buy |
+2,091
| New | +$863K | 0.04% | 210 |
|
|
2019
Q2 | – | Sell |
-5,742
| Closed | -$2.36M | – | 503 |
|
|
2019
Q1 | $2.36M | Buy |
5,742
+595
| +12% | +$245K | 0.06% | 227 |
|
|
2018
Q4 | $1.92M | Buy |
+5,147
| New | +$1.88M | 0.06% | 222 |
|
|
2017
Q3 | – | Sell |
-4,684
| Closed | -$2.3M | – | 204 |
|
|
2017
Q2 | $2.3M | Sell |
4,684
-239
| -5% | -$105K | 0.12% | 72 |
|
|
2017
Q1 | $1.91M | Sell |
4,923
-15,077
| -75% | -$5.59M | 0.12% | 124 |
|
|
2016
Q4 | $7.34M | Buy |
20,000
+16,126
| +416% | +$6.13M | 0.44% | 75 |
|
|
2016
Q3 | $1.56M | Buy |
+3,874
| New | +$1.55M | 0.11% | 127 |
|
Other funds holding REGN
Allstate Corporation's REGN Position: Q2 2026 in Review
Allstate Corporation reduced its Regeneron Pharmaceuticals (REGN) stake by 37% in Q2 2026, selling an estimated $2.77M and leaving 6,878 shares worth $4.29M. The position accounts for 0.04% of the portfolio, ranked #259.
Allstate Corporation first reported a position in REGN in Q3 2016 and has held it in 30 quarters since. The position peaked at $8.46M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Allstate Corporation held 6,878 shares of Regeneron Pharmaceuticals worth $4.29M as of Q2 2026.
- Allstate Corporation sold 4,075 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.77M.
- Regeneron Pharmaceuticals made up 0.04% of Allstate Corporation's portfolio in Q2 2026, its #259 holding.
- Allstate Corporation first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 30 quarters since.
- Allstate Corporation's Regeneron Pharmaceuticals position peaked at $8.46M in Q1 2026.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.